Privo Technologies reports positive results from non-invasive oral cancer and high-grade dysplasia trial

Henlius and Organon secure first US approval for pertuzumab biosimilar POHERDY

BodyLogicMD supports recommendation to remove black box warnings on certain forms of oestrogen

EirGenix signs second global exclusive licensing deal with Sandoz

Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s

ExpreS2ion Biotech signs definitive licensing deal with Serum Institute of India for novel malaria vaccines

Shilpa Medicare completes fourth complex clinical program with positive topline Phase three results for Shilpa's OERIS

iLeukon Therapeutics reveals new clinical results for ILKN421H ongoing first-in-human Phase I trial (NCT05978102)

enGene reports 62% six-month complete response rate for detalimogene in LEGEND trial

FDA approves Promega OncoMate MSI Dx Analysis System as companion diagnostic for KEYTRUDA and LENVIMA in advanced endometrial carcinoma

QIAGEN launches QIAsymphony Connect and showcases new precision oncology advances at AMP 2025

Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL

AN2 Therapeutics partners with GSK to develop boron-based TB therapies; Secures Gates Foundation funding

Exact Sciences secures US exclusive license to Freenome's blood-based colorectal cancer tests

Akeso reveals preclinical research data for novel antagonistic monoclonal antibody aimed at IL-1RAP (AK135)